Ionis Pharmaceuticals Inc (IONS)
34.34
-2.89
(-7.76%)
USD |
NASDAQ |
Nov 15, 16:00
34.31
-0.03
(-0.09%)
Pre-Market: 20:00
Ionis Pharmaceuticals Research and Development Expense (TTM): 912.60M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 912.60M |
| June 30, 2024 | 908.16M |
| March 31, 2024 | 916.03M |
| December 31, 2023 | 899.62M |
| September 30, 2023 | 951.34M |
| June 30, 2023 | 919.00M |
| March 31, 2023 | 869.83M |
| December 31, 2022 | 833.15M |
| September 30, 2022 | 704.45M |
| June 30, 2022 | 706.23M |
| March 31, 2022 | 664.78M |
| December 31, 2021 | 643.45M |
| September 30, 2021 | 634.66M |
| June 30, 2021 | 574.97M |
| March 31, 2021 | 557.93M |
| December 31, 2020 | 535.08M |
| September 30, 2020 | 513.04M |
| June 30, 2020 | 492.32M |
| March 31, 2020 | 476.22M |
| December 31, 2019 | 465.69M |
| September 30, 2019 | 430.40M |
| June 30, 2019 | 421.29M |
| March 31, 2019 | 416.95M |
| December 31, 2018 | 414.60M |
| September 30, 2018 | 429.44M |
| Date | Value |
|---|---|
| June 30, 2018 | 414.40M |
| March 31, 2018 | 396.07M |
| December 31, 2017 | 374.64M |
| September 30, 2017 | 347.51M |
| June 30, 2017 | 351.93M |
| March 31, 2017 | 345.99M |
| December 31, 2016 | 344.32M |
| September 30, 2016 | 344.50M |
| June 30, 2016 | 348.38M |
| March 31, 2016 | 338.81M |
| December 31, 2015 | 322.29M |
| September 30, 2015 | 288.92M |
| June 30, 2015 | 261.49M |
| March 31, 2015 | 252.75M |
| December 31, 2014 | 241.75M |
| September 30, 2014 | 231.23M |
| June 30, 2014 | 215.80M |
| March 31, 2014 | 199.17M |
| December 31, 2013 | 184.03M |
| September 30, 2013 | 169.36M |
| June 30, 2013 | 160.25M |
| March 31, 2013 | 158.06M |
| December 31, 2012 | 158.46M |
| September 30, 2012 | 162.92M |
| June 30, 2012 | 166.29M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
465.69M
Minimum
Dec 2019
951.34M
Maximum
Sep 2023
708.93M
Average
684.61M
Median
Research and Development Expense (TTM) Benchmarks
| Biogen Inc | 2.080B |
| Alnylam Pharmaceuticals Inc | 1.098B |
| Biomarin Pharmaceutical Inc | 779.92M |
| Amicus Therapeutics Inc | 114.20M |
| Arbutus Biopharma Corp | 62.79M |